Chronic Idiopathic Urticaria (CIU) Treatment Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
Chronic Idiopathic Urticaria (CIU) Treatment Market is segmented By Route of Administration (Subcutaneous, Intravenous, Oral), By Molecule Type (Monoclonal Antibody, Small Molecule, Recombinant Fusion Proteins), By Product Type (Mono, Combination), By Development Phase (Phase I, Phase II, Phase III), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of Chronic Idiopathic Urticaria (CIU) Treatment Market
The major players operating in the Chronic Idiopathic Urticaria (CIU) Treatment Market include Taizhou Mabtech Pharmaceutical Co. Ltd., Celldex Therapeutics, Allakos, Novartis, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi, AstraZeneca, UCB Pharma, and Teva Pharmaceuticals.
Chronic Idiopathic Urticaria (CIU) Treatment Market Leaders
- Taizhou Mabtech Pharmaceutical Co. Ltd.
- Celldex Therapeutics
- Allakos
- Novartis
- GlaxoSmithKline
Chronic Idiopathic Urticaria (CIU) Treatment Market - Competitive Rivalry, 2023
Chronic Idiopathic Urticaria (CIU) Treatment Market
(Dominated by major players)
(Highly competitive with lots of players.)